News

cancer chemotherapy survivor

The new guidance, published in JACC, focuses on three classes of commonly used anticancer therapies.

cardiologists going through the certification process

After an official request from Edwards Lifesciences, CMS is rethinking its coverage policy for the use of TAVR to treat asymptomatic severe aortic stenosis. The agency is accepting public comments on this topic until Jan. 14. 

A fifth-generation TAVR valve from Edwards Lifesciences was associated with improved outcomes compared to the device's predecessors in a new real-world analysis out of Cedars Sinai.

doctor in handcuffs after being arrested

On Dec. 11, the Alaskan cardiologist was captured as part of a months-long investigation and charged with 10 counts of possessing child sexual abuse materials. The fire at his home occurred two days later.

old woman or doctor shaking hands with patient

Three out of four TTEs are being ordered by clinicians who are not cardiologists. Could this be having a negative impact on patient care?

The Medtronic Liberant thrombectomy system.

The new device uses an advanced algorithm to regulate aspiration and conserve blood. Ajit Rao, MD, a vascular surgeon with The Mount Sinai Hospital, performed the historic procedure.

Milestone Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for etripamil, a new nasal spray for adult patients with paroxysmal supraventricular tachycardia (PSVT).

Milestone Pharmaceuticals will be selling etripamil under the brand name Cardamyst. It is expected to hit the U.S. market in early 2026.

money business cash flow dollar

Massachusetts-based SpectraWAVE has gained considerable momentum in recent years, planting its flag in some of cardiology’s biggest trends. The company was co-founded by cardiologists and has already secured multiple FDA clearances.

The recall was put in place after a hydrophilic coating was discovered on the inside of the devices. According to the FDA, patients treated with the catheters could face a number of significant risks. 

Abbott’s FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system

Approximately 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors need to be replaced due to a risk of incorrect glucose readings. Abbott has received reports of 736 severe adverse events and seven deaths that may be related to this issue.

heart doctor cardiologist

The timing of this new guidance from the Heart Rhythm Society and American College of Cardiology could not have been better—the document went live just as CMS finalized its decision to cover cardiac ablation procedures performed in ASCs.

Gregg W. Stone, MD, Director of Academic Affairs for the Mount Sinai Health System and Professor of Medicine (Cardiology) and Professor of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai, discusses the ATHENS-HF Trial, a first-in-man study of a chronically-adjustbable, bi-atrial pressure sensing inter-atrial shunt from Adona Medical.

Gregg Stone, MD, spoke to Cardiovascular Business about early data from the ATHENS-HF trial. Ten heart failure patients were treated with the adjustable device, and each implant was a success. 
 

Around the web

One of the tracer’s more significant advantages is its extended half-life of 109 minutes—significantly longer than other currently available PET MPI imaging agents.

Researchers recently used advanced 4D flow MRI to track blood in a pulsating artificial heart, revealing dynamics that closely mirror those of a healthy human organ.

Congress needs to act soon to extend telemedicine services that were greatly expanded under COVID provisions, or they will expire by October. Anders Gilberg, senior vice president of government affairs at the Medical Group Management Association, explains concerns raised by doctors and lawmakers.